NEW YORK, NY / ACCESSWIRE / October 12, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Cabot Oil & Gas Corporation (NYSE:COG)
Investors Affected : October 23, 2015 - June 12, 2020
A class action has commenced on behalf of certain shareholders in Cabot Oil & Gas Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Cabot had inadequate environmental controls and procedures and/or failed to properly mitigate known issues related to those controls and procedures; (ii) as a result, Cabot, among other issues, failed to fix faulty gas wells, thereby polluting Pennsylvania's water supplies through stray gas migration; (iii) the foregoing was foreseeably likely to subject Cabot to increased governmental scrutiny and enforcement, as well as increased reputational and financial harm; (iv) Cabot continually downplayed its potential civil and/or criminal liabilities with respect to such environmental matters; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/cabot-oil-gas-corporation-loss-submission-form/?id=10033&from=1
Lexinfintech Holdings, Ltd. (NASDAQ:LX)
This lawsuit is on behalf of shareholders who purchased or otherwise acquired: (a) Lexin American depositary shares pursuant and/or traceable to the Company's initial public offering conducted on or about December 21, 2017; or (b) Lexin securities between December 21, 2017 and August 24, 2020.
A class action has commenced on behalf of certain shareholders in Lexinfintech Holdings, Ltd. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) LexinFintech reported artificially low delinquency rates by giving borrowers in default new funds to make payments; (2) the Company's business model exposes shareholders to enormous losses by prioritizing Chinese lenders for off-balance sheet loans; (3) the Company exaggerated its user base; (4) the Company was facilitating direct peer to peer lending contrary to Chinese law; (5) the Company engaged in undisclosed related party transactions; (6) the Company lacked adequate internal controls; and (7) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/lexinfintech-holdings-ltd-loss-submission-form/?id=10033&from=1
Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
A class action has commenced on behalf of certain shareholders in Nextcure, Inc. Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
Shareholders may find more information at https://securitiesclasslaw.com/securities/nextcure-inc-loss-submission-form/?id=10033&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: